Corient Private Wealth LP Takes $16.04 Million Position in Illumina, Inc. $ILMN

Corient Private Wealth LP purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the SEC. The firm purchased 91,197 shares of the life sciences company’s stock, valued at approximately $16,035,000. Corient Private Wealth LP owned 0.06% of Illumina at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in Illumina during the 2nd quarter worth $621,000. CW Advisors LLC bought a new position in Illumina during the second quarter worth about $275,000. Marshall Wace LLP grew its stake in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC increased its holdings in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on ILMN shares. Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. TD Cowen boosted their price objective on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Citigroup lifted their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. Finally, Royal Bank Of Canada boosted their price target on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $188.40.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. The trade was a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,034,688 shares of company stock worth $417,970,281. Company insiders own 2.90% of the company’s stock.

Illumina Price Performance

Shares of Illumina stock opened at $215.59 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a 50-day simple moving average of $194.05 and a two-hundred day simple moving average of $155.60. The stock has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a price-to-earnings-growth ratio of 3.20 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.